Q2 FY2026 EarningsQ2 FY2026 results outperformed consensus on the top and bottom lines, with revenue of $773K exceeding the $377K expectation and a narrower net loss of $39.7M vs. the $41.9M anticipated. Verekitug continues to show clinical momentum with Phase 2 COPD enrollment complete and Phase 3 trials for asthma and CRSwNP on track for Q1 2027. Cash reserves of $261.3M provide a runway through 2027, alleviating immediate financing concerns during pivotal trial transitions.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Upstream Bio(UPB) the Revenue is 773 K (-17.5%), Beat estimate;the EBIT is -42.37 M (+4.46%), Beat estimate;the EPS is -0.73 (+1.35%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B17.50%
0.00B59.74%
+0.00B42.24%
EBITExceed expectations
-0.04B4.46%
-0.04B0.54%
+0.00B3.92%
EPSExceed expectations
-0.731.35%
-0.76092.83%
+0.03094.18%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf